Ms Hicklin and colleagues (August 2002 JRSM 1 ) describe two cases of epistaxis after use of sildenafil to enhance penile erection. Such a complication is not unexpected, for two reasons. First, the enzyme inhibited by the drug, cyclic guanosine monophosphate-specific phosphodiesterase type 5 (PDE5), is present at several sites other than the corpus cavernosum, and known effects of the consequent vascular smooth muscle relaxation include headache in 16%, facial flushing in 10%, and hypotension and dizziness in 2% of patients 2 . Second, in-vitro research suggests that sildenafil can inhibit PDE5-induced platelet aggregation 3 . Cerebrovascular haemorrhage is a recognized, albeit rare, side-effect and bleeding from oesophageal varices 4 and from haemorrhoids 5 has been described after use of sildenafil.
In case 2 of Hicklin et al. the patient had been prescribed amlodipine. This drug is metabolized by the same enzyme (cytochrome p450) and could therefore affect the pharmacokinetics of sildenafil, rendering haemorrhage more likely. 3 , indicate that functional coronary artery disease in the presence of seemingly normal coronary arteries may also be caused by abnormal stiffness of the aortic wall (syndrome X). To understand the mechanism, one has to recall the fact that the lion's share of coronary flow occurs during diastole and this flow equals the 'back-flow' from the aortic arch, which is entirely dependent on aortic wall compliance. In other words, during systole the aorta expands proportionally with the pressure and with the elasticity of its wall, and in diastole the flow reverses and the compliant aorta 'pays back' the amount of blood that it stored. As aortic compliance decreases because of fibrosis or for other reasons, so does the aortic back-flow. In severe cases, aortic wall stiffness could lead to coronary underperfusion and myocardial ischaemia.
